Sarah Raifman, MSc
Sarah is a Project Director at ANSIRH, leading a phase IV clinical trial on mail-order pharmacy dispensing of mifepristone for medication abortion in the US. She supports new and established abortion providers around the country offer this novel service to their patients and is evaluating the model's feasibility, acceptability, and safety. Sarah is also part of the Nepal Turnaway Study, a longitudinal study investigating the effects of being denied legal abortion care in Nepal. As a PhD candidate in epidemiology at UCSF, Sarah is studying state policies targeting substance use in pregnancy and their impacts on birth outcomes. She received a BA in Development Studies from Brown University and MSc in Global Health from the Harvard School of Public Health.